For Q2 2026, analysts anticipate Harrow Health will report revenue of $72.42 million and an EPS loss of $0.23, with the current stock price of $62.15 trading below the average analyst price target of $84.00.
Investors are primarily focused on the sales ramp of VEVYE, the company's patented dry eye treatment, which has become the central pillar of Harrow's transition into a branded pharmaceutical leader.
Following successful market share gains in previous quarters, focus remains on prescription volumes and managed care coverage expansion. Analysts will also look for updates on the margin impact of increased marketing spend and the integration of the recently acquired ophthalmic portfolio.